Want to see NRBP full AI Analyst Report?
Top Page
Neorich Biopharma Tech Co Limited
(OTC:NRBP)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.35
▼(-64.70% Downside)
Action:Reiterated
Date:09/22/26
The score is primarily weighed down by very weak financial performance (minimal revenue scale, deeply negative operating profitability, negative operating/free cash flow, and a severely stressed balance sheet with negative equity). Technical indicators are mixed but lean weak with price below the 20-day average and a low RSI, while valuation is unattractive/unclear due to a negative P/E and no dividend yield support.
Positive Factors
Reduced Cash Burn
The substantial reduction in operating cash burn shows some improvement in cash discipline compared with earlier years. Although operations remain cash negative and are not yet self-funding, a smaller deficit could provide a better base for stabilization if the improvement persists.
Negative Factors
Severely Stressed Balance Sheet
Deeply negative equity and debt that is material relative to the very small asset base create significant solvency and financial-flexibility risks. This capital structure can restrict investment, increase dependence on external funding, and leave little protection against further operating losses.
Read all positive and negative factors
Positive Factors
Negative Factors
Reduced Cash Burn
The substantial reduction in operating cash burn shows some improvement in cash discipline compared with earlier years. Although operations remain cash negative and are not yet self-funding, a smaller deficit could provide a better base for stabilization if the improvement persists.
Read all positive factors
Neorich Biopharma Tech Co Limited (NRBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$127.93K
Dividend YieldN/A
Average Volume (3M)323.00
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue Growth167846.30%
EPS Growth-295.83%
CountryUS
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding345,673
10 Day Avg. Volume533
30 Day Avg. Volume323
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-0.25
Price to Sales (P/S)277.91
P/FCF Ratio-28.48
Enterprise Value/Market Cap5.65
Enterprise Value/Revenue302.65
Enterprise Value/Gross Profit-1.81K
Enterprise Value/Ebitda1.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neorich Biopharma Tech Co Limited Business Overview & Revenue Model
Company Description
Pharmagreen Biotech Inc. is a biotechnology solutions provider primarily engaged in cultivating young plant stock for the medical cannabis and CBD hemp industries. Established in 2007, the company operates from its base in Coquitlam, Canada....
Neorich Biopharma Tech Co Limited Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
6
Very Negative
Cash Flow
12
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Neorich Biopharma Tech Co Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $2.91M | -0.43 | -129.54% | ― | -45.76% | -3.77% | |
44 Neutral | $4.20M | -0.08 | -125.01% | ― | ― | 93.91% | |
41 Neutral | $127.93K | -0.20 | 21.06% | ― | 167846.30% | -295.83% | |
19 Underperform | $14.00 | ― | 156.01% | ― | ― | ― |
* Healthcare Sector Average
NRBP
Neorich Biopharma Tech Co Limited
0.37
-0.63
-63.00%
ADTX
Aditxt
0.04
-18,354.78
-100.00%
ADXN
Addex Therapeutics
2.76
-6.63
-70.61%
MSPR
MSP Recovery
0.01
-0.97
-98.98%
BJDX
Bluejay Diagnostics
0.85
-5.27
-86.05%
AKAN
Akanda Corp
2.57
-73.26
-96.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.